UBS Group AG Has $10.90 Million Stock Holdings in Harrow, Inc. $HROW

UBS Group AG grew its stake in Harrow, Inc. (NASDAQ:HROW) by 82.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,362 shares of the company’s stock after buying an additional 100,160 shares during the period. UBS Group AG’s holdings in Harrow were worth $10,896,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the second quarter valued at about $48,000. State of Alaska Department of Revenue acquired a new stake in shares of Harrow in the third quarter valued at about $83,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Harrow by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares during the period. Larson Financial Group LLC grew its stake in Harrow by 848.2% during the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock worth $104,000 after purchasing an additional 1,934 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after purchasing an additional 2,615 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Insider Buying and Selling at Harrow

In related news, CFO Andrew R. Boll bought 3,500 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were bought at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the acquisition, the chief financial officer directly owned 814,679 shares of the company’s stock, valued at $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 12.80% of the stock is owned by corporate insiders.

Harrow Stock Up 1.1%

HROW stock opened at $31.21 on Friday. Harrow, Inc. has a twelve month low of $25.21 and a twelve month high of $54.85. The company has a quick ratio of 2.06, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. The stock’s 50 day moving average is $36.51 and its 200-day moving average is $42.13. The firm has a market capitalization of $1.16 billion, a PE ratio of -76.12 and a beta of 0.34.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The company had revenue of $44.20 million during the quarter, compared to the consensus estimate of $52.43 million. During the same quarter in the prior year, the business earned ($0.38) EPS. Sell-side analysts expect that Harrow, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HROW has been the subject of several recent analyst reports. B. Riley Financial reaffirmed a “buy” rating and set a $65.00 target price (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reaffirmed a “buy” rating and set a $63.00 target price on shares of Harrow in a research note on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, Cantor Fitzgerald decreased their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.43.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.